Please assess the completion status of the following clinical trial:

Trial Title: Phase 2 Dose-Response Study Evaluating the Safety and Efficacy of NCX 470 vs Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of open-angle glaucoma or ocular hypertension in both eyes~* Qualifying IOP at 3 time points throughout the day at 2 visits following washout of IOP-lowering medication, if applicable~* Qualifying best-corrected visual acuity (BCVA) using the Early Treatment of Diabetic Retinopathy Study (ETDRS) protocol in each eye~* Ability to provide informed consent and follow study instructions~Exclusion Criteria:~* Pigmentary or pseudoexfoliative glaucoma~* Narrow anterior chamber angles or disqualifying corneal thickness in either eye~* Clinically significant ocular disease in either eye~* Previous complicated surgery or certain types of glaucoma surgery in either eye~* Incisional ocular surgery or severe trauma in either eye within the past 6 months~* Uncontrolled systemic disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- NCX 470 0.021% (Type: EXPERIMENTAL): NCX 470 Ophthalmic Solution, 0.021% dosed once daily for 4 weeks
- NCX 470 0.042% (Type: EXPERIMENTAL): NCX 470 Ophthalmic Solution, 0.042% dosed once daily for 4 weeks
- NCX 470 0.065% (Type: EXPERIMENTAL): NCX 470 Ophthalmic Solution, 0.065% dosed once daily for 4 weeks
- Latanoprost 0.005% (Type: ACTIVE_COMPARATOR): Latanoprost Ophthalmic Solution, 0.005% dosed once daily for 4 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).